Cargando…

Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements

BACKGROUND: Promotor hypermethylation of CpG islands is common in B cell precursor acute lymphoblastic leukemia (BCP-ALL) with mixed lineage leukemia (MLL) gene rearrangements. Hypomethylating agents (HMA) such as azacitidine (AZA) and decitabine (DEC) reduce DNA hypermethylation by incorporation in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roolf, C., Richter, A., Konkolefski, C., Knuebel, G., Sekora, A., Krohn, S., Stenzel, J., Krause, B. J., Vollmar, B., Murua Escobar, H., Junghanss, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936021/ https://www.ncbi.nlm.nih.gov/pubmed/29728108 http://dx.doi.org/10.1186/s13045-018-0607-3

Ejemplares similares

Combined BCL-2 and PI3K/AKT Pathway Inhibition in KMT2A-Rearranged Acute B-Lymphoblastic Leukemia Cells
por: Holz, Clemens, et al.
Publicado: (2023)

Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia
por: Richter, Anna, et al.
Publicado: (2021)

Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia
por: Richter, Anna, et al.
Publicado: (2019)

The Molecular Subtype of Adult Acute Lymphoblastic Leukemia Samples Determines the Engraftment Site and Proliferation Kinetics in Patient-Derived Xenograft Models
por: Richter, Anna, et al.
Publicado: (2022)

Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia
por: Richter, Anna, et al.
Publicado: (2022)

Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells
por: Roolf, Catrin, et al.
Publicado: (2017)

Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo
por: Richter, Anna, et al.
Publicado: (2020)

Kinetics of Langerhans cell chimerism in the skin of dogs following 2 Gy TBI allogeneic hematopoietic stem cell transplantation
por: Peters, Sabrina, et al.
Publicado: (2016)

Novel Isoquinolinamine and Isoindoloquinazolinone Compounds Exhibit Antiproliferative Activity in Acute Lymphoblastic Leukemia Cells
por: Roolf, Catrin, et al.
Publicado: (2019)

Ultradeep targeted sequencing reveals low allele frequencies of somatic JAK2 and MPL variants in patients with abdominal vein thromboses: results of an ongoing prospective prevalence study in Mecklenburg-West Pomerania
por: Grunwald, Luise, et al.
Publicado: (2020)

Decitabine mildly attenuates MLL‐rearranged acute lymphoblastic leukemia in vivo, and represents a poor chemo‐sensitizer
por: Schneider, Pauline, et al.
Publicado: (2020)

Glycoproteome remodeling in MLL-rearranged B-cell precursor acute lymphoblastic leukemia
por: Oliveira, Tiago, et al.
Publicado: (2021)

The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells
por: Shi, Mingyue, et al.
Publicado: (2019)

Identification of Genes Transcriptionally Responsive to the Loss of MLL Fusions in MLL-Rearranged Acute Lymphoblastic Leukemia
por: van der Linden, Marieke H., et al.
Publicado: (2015)

Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib
por: Sender, Sina, et al.
Publicado: (2021)

MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures
por: Zangrando, Andrea, et al.
Publicado: (2009)

The landscape of somatic mutations in Infant MLL rearranged acute lymphoblastic leukemias
por: Andersson, Anna K, et al.
Publicado: (2015)

Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia
por: Hurtz, Christian, et al.
Publicado: (2019)

The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells
por: Kretzschmar, Christin, et al.
Publicado: (2014)

PROM1 and CTGF Expression in Childhood MLL-Rearrangement Acute Lymphoblastic Leukemia
por: Wang, Lu-lu, et al.
Publicado: (2022)

Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines
por: Sklarz, L.-M., et al.
Publicado: (2020)

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2021)

Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies
por: Kohl, Vanessa, et al.
Publicado: (2019)

Identification of co-expressed genes associated with MLL rearrangement in pediatric acute lymphoblastic leukemia
por: Zhang, Hao, et al.
Publicado: (2020)

Polymorphisms of the murine mitochondrial ND4, CYTB and COX3 genes impact hematopoiesis during aging
por: Kretzschmar, Christin, et al.
Publicado: (2016)

Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin
por: Cruickshank, M N, et al.
Publicado: (2017)

Replication stress in MLL-rearrangements
por: Milyavsky, Michael, et al.
Publicado: (2015)

A Perspective on the Comparative Antileukemic Activity of 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)
por: Momparler, Richard L.
Publicado: (2012)

Identification of hub genes and molecular mechanisms in infant acute lymphoblastic leukemia with MLL gene rearrangement
por: Zhang, Hao, et al.
Publicado: (2019)

EVI1 expression in childhood acute lymphoblastic leukaemia is not restricted to MLL and BCR/ABL rearrangements and is influenced by age
por: Stevens, A, et al.
Publicado: (2014)

Erratum: Replication stress in MLL-rearrangements
por: Milyavsky, Michael, et al.
Publicado: (2016)

MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
por: Winters, Amanda C., et al.
Publicado: (2017)

NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
por: Lopez-Millan, Belen, et al.
Publicado: (2019)

Irinotecan Induces Disease Remission in Xenograft Mouse Models of Pediatric MLL-Rearranged Acute Lymphoblastic Leukemia
por: Kerstjens, Mark, et al.
Publicado: (2021)

Characterization of the novel indolylmaleimides' PDA-66 and PDA-377 effect on canine lymphoma cells
por: Liu, Wen, et al.
Publicado: (2016)

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations
por: Kerstjens, Mark, et al.
Publicado: (2016)

Clofarabine exerts antileukemic activity against cytarabine‐resistant B‐cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression
por: Huang, Meixian, et al.
Publicado: (2018)

RNA binding proteins in MLL-rearranged leukemia
por: Tran, Tiffany M., et al.
Publicado: (2022)

MLL Rearrangements Impact Outcome in HOXA-deregulated T-lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
por: Matlawska-Wasowska, Ksenia, et al.
Publicado: (2016)

Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia
por: Ramsey, Laura B., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sf40dqq9flrufbd01dth89ur1o